: Research published in August 2006 confirmed that Merck did not initially market the drug for weight loss; it was essentially a chemical byproduct of other research into life-saving medicines. Medical and Scientific Context (2006)
: Functional abnormalities noted in users at this time included memory disturbances, impulsivity, and depression. Extasy 09 (2006)
: Contrary to the common myth that it was developed as an appetite suppressant, original documents from the German pharmaceutical company Merck revealed MDMA was first synthesized in 1912 . : Research published in August 2006 confirmed that
The year 2006 was a pivotal time for scientific literature regarding the drug's long-term impact on the human body. Extasy 09 (2006)